Cardinal Health stock (US14149Y1082): Beats Q3 Earnings, Analysts Trim Price Targets

Cardinal Health reported Q3 fiscal 2026 earnings of $3.17 per share, topping consensus by $0.38, but analyst price targets were cut following the April 30 results as peers face valuation pressure.

Cardinal Health reported third-quarter fiscal 2026 earnings on April 30, 2026, delivering an earnings per share of $3.17, which exceeded the consensus estimate of $2.79 by $0.38, according to MarketBeat as of May 14, 2026. The pharmaceutical wholesaler's strong performance reflects healthy growth across brand pharmaceuticals, specialty products, and generics, demonstrating the breadth of its distribution model across retail pharmacy chains, independent pharmacies, mail-order pharmacies, hospital networks, and healthcare providers.

As of: May 14, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Cardinal Health, Inc.
• Sector/industry: Healthcare services and pharmaceutical distribution
• Headquarters/country: Dublin, Ohio, United States
• Core markets: Retail pharmacy chains, independent pharmacies, mail-order pharmacies, hospital networks, healthcare providers
• Key revenue drivers: Branded pharmaceuticals, generic pharmaceuticals, specialty pharmaceutical products
• Home exchange/listing venue: NYSE (CAH)
• Trading currency: USD

Cardinal Health: Core business model

Cardinal Health is one of the three largest pharmaceutical wholesalers in the United States, serving as a critical intermediary in the healthcare supply chain. The company sources and distributes branded, generic, and specialty pharmaceutical products to a broad network of retail and institutional customers. This diversified distribution model provides exposure to multiple revenue streams and customer segments, reducing dependence on any single market segment or customer type.

Main revenue and product drivers for Cardinal Health

The company's Q3 fiscal 2026 results highlighted strength across all major product categories. Brand pharmaceuticals, specialty products, and generics all contributed to the earnings beat, signaling robust demand across the pharmaceutical distribution landscape. The specialty pharmaceutical segment, in particular, has emerged as a growth driver, reflecting the healthcare industry's shift toward higher-margin specialty and biopharmaceutical products. This diversification helps Cardinal Health maintain pricing power and margin stability even as generic drug pricing faces ongoing pressure.

Analyst sentiment and valuation shifts

Following the earnings release, major investment banks adjusted their price targets. On May 1, 2026, Baird lowered its price target on Cardinal Health to $248 from $257 while maintaining an Outperform rating, according to Insider Monkey as of May 14, 2026. Bank of America also reduced its price target to $240 from $260 on April 30, 2026, citing lower peer multiples, while maintaining a Buy rating. The consensus price target across all analysts stands at $241.80, representing approximately 30% upside from the stock's recent trading level of $186.39, according to MarketBeat as of May 14, 2026.

The stock traded at $186.38 USD on May 14, 2026, on the NYSE, reflecting a year-to-date decline of approximately 9.9% from its opening price of $205.62 at the start of 2026. Despite the pullback, Cardinal Health carries a consensus Moderate Buy rating based on 1 strong buy, 15 buy, and 2 hold ratings from covering analysts.

Valuation and market position

Cardinal Health's current valuation reflects a price-to-earnings ratio of approximately 28.5x, which sits above both the broader US healthcare industry average of 23.2x and the peer average of 22.6x. However, independent valuation analysis suggests fair value near $245.27 per share, implying the stock may be undervalued relative to its intrinsic worth despite the elevated P/E multiple. This valuation disconnect highlights the market's cautious stance on pharmaceutical distribution stocks amid ongoing industry consolidation and pricing pressures.

Conclusion

Cardinal Health's Q3 fiscal 2026 earnings beat demonstrates the company's ability to deliver strong operational performance in a competitive pharmaceutical distribution market. While analyst price targets have been trimmed in recent weeks, the consensus view remains constructive, with a Moderate Buy rating and significant upside potential from current levels. For US investors seeking exposure to the healthcare supply chain and pharmaceutical distribution sector, Cardinal Health represents a diversified player with established market position and multiple revenue drivers, though valuation and industry dynamics warrant careful consideration.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.